HCPCS Level II code J9011 represents the injection of datopotamab deruxtecan-dlnk, billed per 1 mg unit. As an antineoplastic biologic administered by injection, this code is relevant for oncology infusion services nationwide and affects hospital outpatient departments, physician offices, and specialty infusion centers. It matters nationally because high-cost oncology injectables influence payer coverage policies, prior authorization workflows, and site-of-care decisions.

Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical service associated with J9011, the typical sites where the drug is administered, and the billing context for unit-based HCPCS reporting. The publication also summarizes benchmark considerations and policy updates that commonly affect HCPCS-level oncology codes, including unitization, billing at the drug acquisition cost, and common modifier use for administration or partial doses.

This summary prepares payers, billing professionals, and oncology practice managers to understand coding implications, reimbursement considerations, and the operational settings in which J9011 is most frequently used. Data not available in the input.